Document is current

Article History

Received: 7 August 2023

Accepted: 10 October 2023

First Online: 18 October 2023

Declarations

:

: Not applicable.

: PL reports research grants/funding from AbbVie and AOBiome; is on the speaker's bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme; reports consulting/advisory boards for Alphyn Biologics, AbbVie, Almirall, Amyris, ASLAN, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Janssen, Johnson & Johnson, Kimberly Clark, LEO Pharma, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Theraplex, UCB, Unilever, Verrica, Yobee Care; stock options with Codex Labs, Concerto Biosci, and, Yobee Care. In addition, Dr. Lio has a patent pending for a Theraplex product with royalties paid and is a Board member and Scientific Advisory Committee Member Emeritus of the National Eczema Association.IA has no relevant disclosures.